269 related articles for article (PubMed ID: 28646725)
1. Eculizumab decreases the procoagulant activity of extracellular vesicles in paroxysmal nocturnal hemoglobinuria: A pilot prospective longitudinal clinical study.
Wannez A; Devalet B; Bouvy C; Laloy J; Bihin B; Chatelain B; Chatelain C; Dogné JM; Mullier F
Thromb Res; 2017 Aug; 156():142-148. PubMed ID: 28646725
[TBL] [Abstract][Full Text] [Related]
2. Prospective and comparative study of paroxysmal nocturnal hemoglobinuria patients treated or not by eculizumab: Focus on platelet extracellular vesicles.
Devalet B; Wannez A; Bailly N; Alpan L; Gheldof D; Douxfils J; Bihin B; Chatelain B; Dogné JM; Chatelain C; Mullier F
Medicine (Baltimore); 2019 Jul; 98(27):e16164. PubMed ID: 31277120
[TBL] [Abstract][Full Text] [Related]
3. Alterations in markers of coagulation and fibrinolysis in patients with Paroxysmal Nocturnal Hemoglobinuria before and during treatment with eculizumab.
van Bijnen ST; Østerud B; Barteling W; Verbeek-Knobbe K; Willemsen M; van Heerde WL; Muus P
Thromb Res; 2015 Aug; 136(2):274-81. PubMed ID: 26143713
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil activation and nucleosomes as markers of systemic inflammation in paroxysmal nocturnal hemoglobinuria: effects of eculizumab.
van Bijnen ST; Wouters D; van Mierlo GJ; Muus P; Zeerleder S
J Thromb Haemost; 2015 Nov; 13(11):2004-11. PubMed ID: 26333021
[TBL] [Abstract][Full Text] [Related]
5. Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria.
Schrezenmeier H; Höchsmann B
Expert Rev Hematol; 2009 Feb; 2(1):7-16. PubMed ID: 21082989
[TBL] [Abstract][Full Text] [Related]
6. Perisurgical induction of eculizumab in a patient with paroxysmal nocturnal hemoglobinuria: its inhibition of surgery-triggered hemolysis and the consequence of subsequent discontinuation.
Kurita N; Obara N; Fukuda K; Nishikii H; Sato S; Inagawa S; Kurokawa T; Owada Y; Ninomiya H; Chiba S
Blood Coagul Fibrinolysis; 2013 Sep; 24(6):658-62. PubMed ID: 23917586
[TBL] [Abstract][Full Text] [Related]
7. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
Notaro R; Sica M
Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
[TBL] [Abstract][Full Text] [Related]
8. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
Keating GM; Lyseng-Williamson KA; McKeage K
BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
[TBL] [Abstract][Full Text] [Related]
9. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
[TBL] [Abstract][Full Text] [Related]
10. Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab.
Macrae FL; Peacock-Young B; Bowman P; Baker SR; Quested S; Linton E; Hillmen P; Griffin M; Munir T; Payne D; McKinley C; Clarke D; Newton DJ; Hill A; Ariëns RAS
Am J Hematol; 2020 Aug; 95(8):944-952. PubMed ID: 32311169
[TBL] [Abstract][Full Text] [Related]
11. Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study.
Loschi M; Porcher R; Barraco F; Terriou L; Mohty M; de Guibert S; Mahe B; Lemal R; Dumas PY; Etienne G; Jardin F; Royer B; Bordessoule D; Rohrlich PS; Fornecker LM; Salanoubat C; Maury S; Cahn JY; Vincent L; Sene T; Rigaudeau S; Nguyen S; Lepretre AC; Mary JY; Corront B; Socie G; Peffault de Latour R
Am J Hematol; 2016 Jun; 91(4):366-70. PubMed ID: 26689746
[TBL] [Abstract][Full Text] [Related]
12. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria.
Kelly RJ; Höchsmann B; Szer J; Kulasekararaj A; de Guibert S; Röth A; Weitz IC; Armstrong E; Risitano AM; Patriquin CJ; Terriou L; Muus P; Hill A; Turner MP; Schrezenmeier H; Peffault de Latour R
N Engl J Med; 2015 Sep; 373(11):1032-9. PubMed ID: 26352814
[TBL] [Abstract][Full Text] [Related]
13. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Muus P; Dührsen U; Risitano AM; Schubert J; Luzzatto L; Schrezenmeier H; Szer J; Brodsky RA; Hill A; Socié G; Bessler M; Rollins SA; Bell L; Rother RP; Young NS
Blood; 2007 Dec; 110(12):4123-8. PubMed ID: 17702897
[TBL] [Abstract][Full Text] [Related]
14. Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria.
Sicre de Fontbrune F; Peffault de Latour R
Semin Hematol; 2018 Jul; 55(3):124-129. PubMed ID: 30032748
[TBL] [Abstract][Full Text] [Related]
15. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
[TBL] [Abstract][Full Text] [Related]
16. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.
Hallstensen RF; Bergseth G; Foss S; Jæger S; Gedde-Dahl T; Holt J; Christiansen D; Lau C; Brekke OL; Armstrong E; Stefanovic V; Andersen JT; Sandlie I; Mollnes TE
Immunobiology; 2015 Apr; 220(4):452-9. PubMed ID: 25468724
[TBL] [Abstract][Full Text] [Related]
17. Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation.
Weitz IC; Razavi P; Rochanda L; Zwicker J; Furie B; Manly D; Mackman N; Green R; Liebman HA
Thromb Res; 2012 Sep; 130(3):361-8. PubMed ID: 22542362
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review.
Miyasaka N; Miura O; Kawaguchi T; Arima N; Morishita E; Usuki K; Morita Y; Nishiwaki K; Ninomiya H; Gotoh A; Imashuku S; Urabe A; Shichishima T; Nishimura J; Kanakura Y
Int J Hematol; 2016 Jun; 103(6):703-12. PubMed ID: 26857155
[TBL] [Abstract][Full Text] [Related]
19. Paroxysmal nocturnal hemoglobinuria: Test to monitor the action of eculizumab treatment.
Arcavi M; Ceballo F; Caracciolo MB; Lazarowski A
Int J Lab Hematol; 2020 Jun; 42(3):335-340. PubMed ID: 32202389
[TBL] [Abstract][Full Text] [Related]
20. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.
Peffault de Latour R; Fremeaux-Bacchi V; Porcher R; Xhaard A; Rosain J; Castaneda DC; Vieira-Martins P; Roncelin S; Rodriguez-Otero P; Plessier A; Sicre de Fontbrune F; Abbes S; Robin M; Socié G
Blood; 2015 Jan; 125(5):775-83. PubMed ID: 25477495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
